Format

Send to

Choose Destination
An Pediatr (Barc). 2015 Mar;82(3):199.e1-2. doi: 10.1016/j.anpedi.2014.10.004. Epub 2014 Nov 11.

[Update of recommendations on the use of palivizumab as prophylaxis in RSV infections].

[Article in Spanish]

Author information

1
Servicio de Neonatología, Hospital Clínic, Facultad de Medicina, Barcelona, España. Electronic address: jfiguer@clinic.ub.es.
2
Servicio de Neonatología, Hospital Clínic, Facultad de Medicina, Barcelona, España.

Abstract

The Standards Committee of the Spanish Neonatology Society (SENeo) considers that the new document from the American Academy of Pediatrics, including recommendations for palivizumab use to prevent serious infections produced by the Respiratory Syncytial Virus (RSV), provides no new scientific evidence which would justify the modification of the current recommendations of the SENeo. However, some adjustments to the criteria of the existing recommendations are proposed to reduce the cost of the drug by its correct and judicious management.

KEYWORDS:

Bronchiolitis; Bronquiolitis; Palivizumab; Prematuros; Preterm infants; Prevención; Prevention; Respiratory syncytial virus; Virus respiratorio sincitial

PMID:
25453311
DOI:
10.1016/j.anpedi.2014.10.004
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Ediciones Doyma, S.L.
Loading ...
Support Center